Dianthus Therapeutics, Inc. (DNTH) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$162M, a net margin of -7973.3%; the best year in this period was 2016 with -$9M.
Over the twelve months to September 30, 2026, revenue was $3M and net income -$202M.
Free cash flow was -$129M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 1755196% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3M | $2M | $6M | $3M | — | — | — | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$236M | -$178M | -$102M | -$48M | -$30M | -$75M | -$79M | -$83M | -$60M | -$36M | -$9M |
| Net income | -$202M | -$162M | -$85M | -$44M | -$28M | -$71M | -$75M | -$77M | -$58M | -$35M | -$9M |
| EPS (diluted) | $-4.08 | $-4.20 | $-2.55 | $-8.45 | $-32.57 | $-87.61 | $-116.13 | $-140.58 | $-212.57 | $-1298.51 | $-4424.57 |
| R&D | $189M | $146M | $83M | $33M | $29M | $47M | $51M | $59M | $41M | $28M | $6M |
| Revenue growth | — | −67.3% | +120.6% | — | — | — | — | — | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$175M | -$129M | -$78M | -$37M | -$29M | -$60M | -$64M | -$57M | -$42M | -$22M | -$7M |
| Capital spending | -$697000 | -$213000 | -$105000 | -$110000 | -$314000 | -$1M | -$400000 | -$3M | -$8M | -$2M | -$139000 |
| Free cash flow | -$176M | -$129M | -$78M | -$37M | -$29M | -$61M | -$64M | -$60M | -$50M | -$24M | -$7M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $41M | $23M | $13M | $3M | $2M | $10M | $10M | $10M | $11M | $2M | $662000 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $404M | $275M | $174M | $75M | $177M | $149M | $146M | $143M | $51M | $5M |
| Debt | — | $1M | $1M | $585000 | $30M | $0 | $0 | $0 | $0 | $0 | — |
| Equity | — | $493M | $352M | $169M | -$44M | -$17M | $144M | $141M | $146M | -$42M | -$9M |
| Total assets | — | $531M | $374M | $179M | $83M | $190M | $162M | $162M | $157M | $54M | — |
| Shares (diluted) | 57M | 39M | 33M | 5M | 1M | 1M | 1M | 1M | 0M | 0M | 0M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | -8683.9% | -8739.3% | -1633.7% | -1704.7% | — | — | — | — | — | — | — |
| Net margin | -7436.5% | -7973.3% | -1362.8% | -1541.2% | — | — | — | — | — | — | — |
| FCF margin | -6469.9% | -6349.4% | -1255.6% | -1308.2% | — | — | — | — | — | — | — |
| ROIC | — | -28.4% | -22.7% | -22.5% | — | — | -43.2% | -46.4% | -32.5% | — | — |
| ROE | — | -32.9% | -24.1% | -25.8% | 64.2% | 412.4% | -52.1% | -54.4% | -39.5% | 84.3% | 106.3% |
Frequently asked questions
What is Dianthus Therapeutics’s annual revenue?
$2M in fiscal 2025 and $3M over the twelve months to September 30, 2026.
How much profit does Dianthus Therapeutics make?
Net income was -$162M in fiscal 2025 (net margin -7973.3%).
Is Dianthus Therapeutics’s revenue growing?
No: revenue fell 67.3% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.